ASCO's 44th annual conference May 30-June 3

J, no> wrote:

> http://afp.google.com/article/ALeqM5...cQdBiezSGC4Wsg
> [Excerpt]
> The results of around 30 clinical trials are due to be presented during
> the five day conference, with attendance expected to top 30,000.
>
> Most of the clinical trials are to present advances in breast cancer, the
> top cancer killer among women worldwide, and lung cancer which is the
> deadliest form of cancer, causing 1.3 million death around the globe each
> year according to the World Health Organization.
>
> One of the clinical trials on lung cancer involves Cetuximab, marketed as
> Erbitux by the pharmaceutical giant Merck, which is administered
> intravenously in combination with chemotherapy.
>
> Another trial examines the potential of the anti-inflammatory drug
> Celebrex to impact cancer in smokers and former smokers.